Plain-English translation of NCT07805707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing an mRNA seasonal flu vaccine in older adults to see how well it prevents flu illness compared to the standard flu vaccine that is already approved and used. The mRNA Seasonal Flu Vaccine works by teaching your body's immune system to recognize and fight the flu virus. Researchers will track participants throughout the flu season to measure how many people stay healthy, monitor for side effects, and measure how well the immune system responds.
Current flu vaccines work reasonably well, but older adults often have weaker immune responses to them. This new type of vaccine technology may provide better protection against the flu in people aged 65 and older, who are at highest risk of serious flu complications.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of either the new mRNA flu vaccine or the standard flu vaccine on Day 1. After that, you will be followed throughout the flu season so researchers can monitor whether you get the flu, check for any side effects, and measure your immune response to the vaccine. The study involves about 54,000 participants total, and you will not know which vaccine you received (this is called 'observer-blind').
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States